Superseded public profile

In clinical trials↗Metabolic↗

Superseded · version 2: Amycretin↗

An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. 1

What this version reported

ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.↗

Organizations named in cited records:
  • Novo Nordisk A/S↗

Trial records: NCT06049329

Sources for this version

  1. 1
    Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026